Search

Your search keyword '"Cobleigh M"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Cobleigh M" Remove constraint Author: "Cobleigh M" Search Limiters Full Text Remove constraint Search Limiters: Full Text
31 results on '"Cobleigh M"'

Search Results

3. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

6. Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry

7. First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry

8. Abstract P5-08-27: Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry

9. Abstract P5-08-08: Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR– HER2+ disease from the SystHERs registry

13. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

14. Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates

16. NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx).

17. Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates.

19. Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.

20. Comparison of gut microbiome composition in colonic biopsies, endoscopically-collected and at-home-collected stool samples.

21. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.

22. Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.

23. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.

24. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.

25. Influence of breast reconstruction on technical aspects of echocardiographic image acquisition compared with physician-assessed image quality.

26. Somatic variants of potential clinical significance in the tumors of BRCA phenocopies.

27. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

28. Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

29. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

30. Growth of human squamous head and neck cancer in vitro.

31. Culture of squamous head and neck cancer on 3T3 fibroblasts following isokinetic velocity sedimentation.

Catalog

Books, media, physical & digital resources